Search results: (10000)
News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.
News Complex Impacts of Obesity on the Brains of People with Psychiatric Disorders
Obesity in individuals with bipolar disorder or schizophrenia is closely linked not only to higher mortality but also to worse progression of the psychiatric illness, lower response to psychiatric treatment, more frequent fatal outcomes (suicide), deterioration in cognitive functions, and structural brain damage. In his lecture at the XIV Congress of the Psychiatric Society of the Czech Medical Association J.E. Purkyně in Mikulov in June 2022, Professor Tomáš Hájek from Dalhousie University in Halifax, Canada, focused on these connections.
News An Introductory Word to the Section on Hereditary Angioedema — MUDr. Roman Hakl, Ph.D.
Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).
News Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management
Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under the chosen dressing. Zetuvit Plus Silicone Border dressing with high absorbent and retention capacity offers confidence in treating both chronic and acute wounds and high comfort for the patient.
News What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?
How has the life of patients who now have the opportunity to treat diabetes mellitus in general practice changed? And what do the current prescription conditions for modern antidiabetics bring to their treating physicians? We discuss this and more with diabetologist MUDr. Katarína Nováková.
News Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension. Although it is an unpleasant complication, it does not – and should not – always be a reason to discontinue therapy. Fear of hypotension should not lead to not prescribing sacubitril/valsartan at all. We provide practical guidance on how to approach this clinical situation.
News Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium bromide (LAMA), Enerzair® for maintenance inhalation treatment of bronchial asthma, approved in the EU last year, have established health insurance coverage in the Czech Republic from May 1, 2021. We bring a summary of the conditions for reimbursement.
News Calculator Naxiva - Application for Easy Prescription of Medical Cannabis Extracts
The new Calculator Naxiva application, specifically designed for doctors prescribing medical cannabis, allows for a simple conversion of its doses to the Naxiva Panaxol extract. Quickly and easily, the required amount of extract for a particular patient can be calculated.
News Satisfaction of Patients Treated with Platinum Derivatives with Antiemetic Therapy
The fixed oral combination of netupitant with palonosetron (NEPA) is used for the prevention of nausea and vomiting induced by cytotoxic chemotherapy. A prospective German study evaluated the benefit of this therapy on the quality of life of patients treated with platinum derivatives.
News Current Recommendations by the ELN Expert Panel on AML Diagnosis Management
The 2022 recommendations from European LeukemiaNet (ELN) add new information to the previous recommendations from 2010 and 2017. They concern the diagnosis and treatment of acute myeloid leukemia (AML) in adults from the perspective of pathogenesis, disease classification adjustment, possibilities of genomic diagnosis, and the inclusion of minimal residual disease (MRD) assessment.
News Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study
The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type 2 diabetes mellitus (T2DM) and chronic heart failure regardless of ejection fraction value. Its impact on renal function and the prognosis of patients with chronic kidney disease (CKD) irrespective of the presence of T2DM was specifically evaluated in the double-blind placebo-controlled EMPA-KIDNEY study.
News Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving remission or reducing disease activity by 90-100% from the baseline state (PASI 90-100) is highly probable, especially when using biological drugs from the IL-17 or IL-23 inhibitor groups. However, individually, patients may exhibit primary or secondary resistance even when using these preparations, necessitating a change in biological treatment. The following case study presents the case of a young man who achieved complete disease remission with bimekizumab after the previous failure of ixekizumab and risankizumab.
News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?
Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.
News How to Communicate and Receive an Oncological Diagnosis
Communicating the truth to a patient about their health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system started emphasizing this aspect, i.e., honest and open communication between doctor and patient, several years after the Velvet Revolution.
News Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice in the USA
A recently published study summarizes the characteristics of patients newly treated with tofacitinib for ulcerative colitis (UC), the impact of initiating tofacitinib on corticosteroid use, and adherence to this treatment in real-world practice based on a retrospective analysis of data from a large health database in the USA.
News Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation
How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory Bowel Diseases.
News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy
Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.
News High-Dose Cyclophosphamide in Hard-to-Treat Patients with B-NHL
For hard-to-treat patients with non-Hodgkin lymphoma, cyclophosphamide administered in one or two cycles can help bridge the period needed to obtain other effective treatments, as inferred from the work of French authors recently published in the European Journal of Haematology.
News COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
In a retrospective study examining the impact of COVID-19 on immune thrombocytopenic purpura, Spanish authors surprisingly observed a paradoxical effect.
News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery
Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.
News Effect of Initiation of Warfarin Therapy on the Risk of Ischemic Stroke
Anticoagulant therapy is essential in patients with atrial fibrillation for the prevention of thromboembolic events. Warfarin is a highly effective anticoagulant, but the introduction of new oral anticoagulants (NOACs) has offered certain advantages over it. Shortly after starting warfarin therapy, patients have repeatedly been shown to have a paradoxically increased risk of developing ischemic stroke. The aim of the study presented below was to determine whether this increase in risk is associated with the initiation of anticoagulant therapy.
News Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH levels above the upper reference limit is well documented, but according to two recently published population studies, mortality in patients treated with levothyroxine is also increased when TSH levels are below the lower reference limit.
News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.
News Micronized Diosmin and Flavonoid Fraction – What Do They Have in Common?
Micronized diosmin and micronized purified flavonoid fraction are medications from the flavonoid group that are used as venopharmaceuticals/venoprotectives in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both have many common properties, which we discuss in the following text. Their differences will be covered in a follow-up article on this topic.